ResearcherUniversity of PaduaActive in the last 2 years
Ildikò Szabó
Matched on ORCID iD 0000-0002-3637-3947; OpenAlex author ID A5075678380. Sources: OpenAlex.
Their work
- Papers
- 9 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 44
2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 3 papers · 2024: none · 2025: none · 2026: 2 papers
Papers 9
- Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B receptor ligand strongly reduces pancreati… Last author DOI 10.1016/j.phrs.2026.108150↗
- pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/apha.70183↗
- Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ductal adenocarcinoma cells in vitro and in v… Co-author DOI 10.1007/s00109-023-02290-y↗
- Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00109-023-02331-6↗
- DA7R: A 7-Letter Zip Code to Target PDAC. Co-author DOI 10.3390/pharmaceutics15051508↗
- Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancreatic Ductal Adenocarcinoma in an Immunoc… Co-author DOI 10.3390/cancers14112618↗
- Targeting Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.33594/000000326↗
- Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma. Last author DOI 10.18632/oncotarget.11299↗
- Regulation of Proliferation by a Mitochondrial Potassium Channel in Pancreatic Ductal Adenocarcinoma Cells. Co-author DOI 10.3389/fonc.2017.00239↗
Closest collaborators
The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Erich Gulbins · 4 shared papers, 2022–2026 · strength 0.71
- Paper Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B re… DOI 10.1016/j.phrs.2026.108150↗
- Paper Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. DOI 10.1007/s00109-023-02331-6↗
- Paper Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ducta… DOI 10.1007/s00109-023-02290-y↗
- Lucia Biasutto · 4 shared papers, 2017–2026 · strength 0.67
- Paper Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B re… DOI 10.1016/j.phrs.2026.108150↗
- Paper DA7R: A 7-Letter Zip Code to Target PDAC. DOI 10.3390/pharmaceutics15051508↗
- Paper Targeting Pancreatic Ductal Adenocarcinoma (PDAC). DOI 10.33594/000000326↗
- Sofia Parrasia · 3 shared papers, 2021–2026 · strength 0.61
- Paper Tumor-specific targeting of a mitochondrial Kv1.3 channel inhibitor through conjugation to gastrin/cholecystokinin B re… DOI 10.1016/j.phrs.2026.108150↗
- Paper DA7R: A 7-Letter Zip Code to Target PDAC. DOI 10.3390/pharmaceutics15051508↗
- Paper Targeting Pancreatic Ductal Adenocarcinoma (PDAC). DOI 10.33594/000000326↗
- Gregory C. Wilson · 3 shared papers, 2022–2023 · strength 0.48
- Paper Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. DOI 10.1007/s00109-023-02331-6↗
- Paper Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ducta… DOI 10.1007/s00109-023-02290-y↗
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618↗
- Sameer H. Patel · 3 shared papers, 2022–2023 · strength 0.48
- Paper Acid sphingomyelinase expression is associated with survival in resectable pancreatic ductal adenocarcinoma. DOI 10.1007/s00109-023-02331-6↗
- Paper Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ducta… DOI 10.1007/s00109-023-02290-y↗
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618↗
- Syed Ameen Ahmad · 2 shared papers, 2022–2023 · strength 0.30
- Paper Simultaneous targeting of mitochondrial Kv1.3 and lysosomal acid sphingomyelinase amplifies killing of pancreatic ducta… DOI 10.1007/s00109-023-02290-y↗
- Paper Inhibition of a Mitochondrial Potassium Channel in Combination with Gemcitabine and Abraxane Drastically Reduces Pancre… DOI 10.3390/cancers14112618↗
- Anna Trauzold · 2 shared papers, 2017–2026 · strength 0.25
- Vincenzo Corbo · 1 shared paper, 2026 · strength 0.23
- Alessandro Carrer · 1 shared paper, 2026 · strength 0.23
- Elena Fiorini · 1 shared paper, 2026 · strength 0.23
- Carlotta Paoli · 1 shared paper, 2026 · strength 0.23
- Pawel Swietach · 1 shared paper, 2026 · strength 0.19
- Sofie Hagelund · 1 shared paper, 2026 · strength 0.19
- Verena Hofschröer · 1 shared paper, 2026 · strength 0.19
- Laura Mezzanotte · 1 shared paper, 2026 · strength 0.19
- Zoltán Pethő · 1 shared paper, 2026 · strength 0.19
- Tiago M. A. Carvalho · 1 shared paper, 2026 · strength 0.19
- Stephan J. Reshkin · 1 shared paper, 2026 · strength 0.19
- Torsten Hechler · 1 shared paper, 2026 · strength 0.19
- Rosa Angela Cardone · 1 shared paper, 2026 · strength 0.19
- Julie Schnipper · 1 shared paper, 2026 · strength 0.19
- Wiktoria Błaszczak · 1 shared paper, 2026 · strength 0.19
- Frauke Alves · 1 shared paper, 2026 · strength 0.19
- Ganga Deshar · 1 shared paper, 2026 · strength 0.19
- Ivana Novak · 1 shared paper, 2026 · strength 0.19
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.